Each January, the brightest minds in colorectal cancer research meet at the Gastrointestinal Cancer Symposium.
Fight Colorectal Cancer and The Colon Cancer Alliance are partnering to bring you the big news in colorectal cancer from the symposium. Dr. Allyson Ocean will be presenting.
Get insights about new types of treatments on the horizon, diagnostic tests available, research for upcoming drugs/biomarkers and the way colorectal cancer is treated. We’ll take a look back and a look forward. You’re not going to want to miss it.
Fight Colorectal Cancer’s Medical Advisory Board Member, Axel Grothey, MD, focused this webinar to stage III colon cancer patients. Dr. Grothey, medical oncologist at Mayo Clinic, will spend the hour discussing current treatment options and exciting new research that pertains to stage III colon cancer patients.
Have you or someone you love recently been diagnosed with stage III or stage IV colorectal cancer? Feeling overwhelmed? Learn where to go from here.
We’ll talk about every leg of the journey from understanding your diagnosis to tips on building your treatment team.
Join Dr. Edward Crane to better understand your options for treatment and know that you are not alone in your diagnosis.
A public webinar to increase awareness on breast cancer. This presentation covers simple facts on occurrence of breast cancer, its risk factors and various symptoms besides briefly highlighting the multitude of treatment options available. Presented in simple layman terms for broad understanding.
Fight Colorectal Cancer’s Medical Advisory Board Member, Axel Grothey, MD, focused this webinar to stage III colon cancer patients. Dr. Grothey, medical oncologist at Mayo Clinic, will spend the hour discussing current treatment options and exciting new research that pertains to stage III colon cancer patients.
Have you or someone you love recently been diagnosed with stage III or stage IV colorectal cancer? Feeling overwhelmed? Learn where to go from here.
We’ll talk about every leg of the journey from understanding your diagnosis to tips on building your treatment team.
Join Dr. Edward Crane to better understand your options for treatment and know that you are not alone in your diagnosis.
A public webinar to increase awareness on breast cancer. This presentation covers simple facts on occurrence of breast cancer, its risk factors and various symptoms besides briefly highlighting the multitude of treatment options available. Presented in simple layman terms for broad understanding.
In this webinar our Medical Advisory Board member Dr. Dennis Ahnen will cover the basics of colorectal cancer – the hows, whats, and whys.
This August 2015 webinar is brought to you by Fight CRC’s Research Advocacy Training and Support (RATS) program. http://fightcolorectalcancer.org/do-something/support-research/research-advocacy-training-and-support-rats/
I and 4 other classmates researched Colorectal Cancer, commonly called Colon Cancer, and presented before our class about what we learned. Our presentation covered the pathophysiology, epidemiology, risk factors, screenings, signs and symptoms, assessments and diagnostic tests, diagnostic criteria, treatments, and article on evidence based practices.
Mary Mulkerin, BSN, RN, will discuss various issues related to rectal cancer, including incidence and prevalence, standard therapy and the role of surgery. In addition, she will address specific concerns that come up for those living as rectal cancer survivors.
Each January, the best and brightest minds in colorectal cancer research meet at the Gastrointestinal Cancers Symposium. Fight Colorectal Cancer and the Colon Cancer Alliance are partnering to bring you the big news in colorectal cancer from the 2013 symposium.
Join us to learn more about these topics:
- Can aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) keep cancer from returning?
- The relationship of body mass index (BMI) and exercise in colorectal cancer
- What scientists are learning about how your immune system can fight cancer
- The latest on what biomarkers can tell us about your cancer
- Rectal cancer treatment that is based on your biological make-up
The webinar will be led by Dr. Richard Goldberg, an internationally renowned gastrointestinal oncologist who specializes in colorectal cancer. He is a tenured professor in the Department of Internal Medicine at The Ohio State University and serves as physician-in-chief at Ohio State’s Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
Dr. Murphy presents slides discussing general screening trends in the US, including how the US compares to other countries, different screening modalities, and differences in screening by:
-Age
-Gender
-Geography
-Race/Ethnicity
Colorectal Cancer Detection: Fact vs FictionJarrod Lee
Colorectal cancer is the most common cancer in Singapore. It can be prevented by timely screening. Yet there are many misconceptions about colorectal cancer screening. This talk addresses some of the common perceptions about colorectal cancer screening. This talk was first presented to the public at Feel Fab Fest 2018.
Understanding the Screening Options from the new USPSTF Colorectal Cancer Scr...Ryan Kerr
The Colorectal Cancer Task Force is a subcommittee within the Colorado Cancer Coalition.
Our goal is to improve colorectal cancer outcomes in the state of Colorado.
This presentation gives a high-level overview of each of the colorectal cancer screening options mentioned in the new United States Preventive Services Task Force (USPSTF) screening guidelines (released June 2016).
Colon cancer epidemiology, risk factors, and etiology, pathology, screening, diagnosis, workup, staging, treatment, chemotherapy and follow-up.
These slides are selections from the major references in surgery, oncology, and internal medicine. I have tried to gather the information from valid and recently-updated references such as NCCN guidelines and Cancer statistics. I hope it helps!
A seminar on colon cancer including topics of Epidemiology, Aetiology, Molecular Biology, Pathology, Clinical presentation, Screening, Diagnosis and Staging.
Information about Colorectal cancer by Dr Dhaval Mangukiya.
Details of Colorectal cancer, Epidemiology, Risk Factors, Protective Factors, Pathology, Prognostic Determinants, Clinical Presentation, Rectal Cancer, Dignosis, Differential Diagnosis, Staging and Management etc.
https://drdhavalmangukiya.com/
http://www.youtube.com/c/DrDhavalMangukiyaGastrosurgeonSurat
https://gastrosurgerysurat.blogspot.com/
The Early Age Onset (EAO) Colorectal Cancer (CRC) Summit was a novel meeting designed for Early Age Onset (EAO) colorectal cancer (CRC) survivors, affected families as well as physicians and scientists who were interested in advancing their understanding of the rapidly increasing incidence of rectal and colon cancer among young adults under 50 years of age.
Co-hosted by the Colon Cancer Challenge Foundation and the CME office of Memorial Sloan Kettering Cancer Center the program provided an opportunity to hear leading clinicians and scientists on the epidemiology, pathogenesis, genomics and lifestyle challenges of EAO-CRC.
The course also included lectures as well as workshops and panel discussions designed to facilitate multidisciplinary consensus regarding the priorities of EAO-CRC prevention, clinical care and research moving forward.
In this webinar our Medical Advisory Board member Dr. Dennis Ahnen will cover the basics of colorectal cancer – the hows, whats, and whys.
This August 2015 webinar is brought to you by Fight CRC’s Research Advocacy Training and Support (RATS) program. http://fightcolorectalcancer.org/do-something/support-research/research-advocacy-training-and-support-rats/
I and 4 other classmates researched Colorectal Cancer, commonly called Colon Cancer, and presented before our class about what we learned. Our presentation covered the pathophysiology, epidemiology, risk factors, screenings, signs and symptoms, assessments and diagnostic tests, diagnostic criteria, treatments, and article on evidence based practices.
Mary Mulkerin, BSN, RN, will discuss various issues related to rectal cancer, including incidence and prevalence, standard therapy and the role of surgery. In addition, she will address specific concerns that come up for those living as rectal cancer survivors.
Each January, the best and brightest minds in colorectal cancer research meet at the Gastrointestinal Cancers Symposium. Fight Colorectal Cancer and the Colon Cancer Alliance are partnering to bring you the big news in colorectal cancer from the 2013 symposium.
Join us to learn more about these topics:
- Can aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) keep cancer from returning?
- The relationship of body mass index (BMI) and exercise in colorectal cancer
- What scientists are learning about how your immune system can fight cancer
- The latest on what biomarkers can tell us about your cancer
- Rectal cancer treatment that is based on your biological make-up
The webinar will be led by Dr. Richard Goldberg, an internationally renowned gastrointestinal oncologist who specializes in colorectal cancer. He is a tenured professor in the Department of Internal Medicine at The Ohio State University and serves as physician-in-chief at Ohio State’s Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
Dr. Murphy presents slides discussing general screening trends in the US, including how the US compares to other countries, different screening modalities, and differences in screening by:
-Age
-Gender
-Geography
-Race/Ethnicity
Colorectal Cancer Detection: Fact vs FictionJarrod Lee
Colorectal cancer is the most common cancer in Singapore. It can be prevented by timely screening. Yet there are many misconceptions about colorectal cancer screening. This talk addresses some of the common perceptions about colorectal cancer screening. This talk was first presented to the public at Feel Fab Fest 2018.
Understanding the Screening Options from the new USPSTF Colorectal Cancer Scr...Ryan Kerr
The Colorectal Cancer Task Force is a subcommittee within the Colorado Cancer Coalition.
Our goal is to improve colorectal cancer outcomes in the state of Colorado.
This presentation gives a high-level overview of each of the colorectal cancer screening options mentioned in the new United States Preventive Services Task Force (USPSTF) screening guidelines (released June 2016).
Colon cancer epidemiology, risk factors, and etiology, pathology, screening, diagnosis, workup, staging, treatment, chemotherapy and follow-up.
These slides are selections from the major references in surgery, oncology, and internal medicine. I have tried to gather the information from valid and recently-updated references such as NCCN guidelines and Cancer statistics. I hope it helps!
A seminar on colon cancer including topics of Epidemiology, Aetiology, Molecular Biology, Pathology, Clinical presentation, Screening, Diagnosis and Staging.
Information about Colorectal cancer by Dr Dhaval Mangukiya.
Details of Colorectal cancer, Epidemiology, Risk Factors, Protective Factors, Pathology, Prognostic Determinants, Clinical Presentation, Rectal Cancer, Dignosis, Differential Diagnosis, Staging and Management etc.
https://drdhavalmangukiya.com/
http://www.youtube.com/c/DrDhavalMangukiyaGastrosurgeonSurat
https://gastrosurgerysurat.blogspot.com/
The Early Age Onset (EAO) Colorectal Cancer (CRC) Summit was a novel meeting designed for Early Age Onset (EAO) colorectal cancer (CRC) survivors, affected families as well as physicians and scientists who were interested in advancing their understanding of the rapidly increasing incidence of rectal and colon cancer among young adults under 50 years of age.
Co-hosted by the Colon Cancer Challenge Foundation and the CME office of Memorial Sloan Kettering Cancer Center the program provided an opportunity to hear leading clinicians and scientists on the epidemiology, pathogenesis, genomics and lifestyle challenges of EAO-CRC.
The course also included lectures as well as workshops and panel discussions designed to facilitate multidisciplinary consensus regarding the priorities of EAO-CRC prevention, clinical care and research moving forward.
How to have quality of life in Advanced ovarian malignancyRajesh Gajbhiye
Presentation given by Dr Rakhi Gajbhiye, Mauli Hospital Nagpur at MGIMS sewagram for an International conference on Womens Health Fatal Disorders Survival with Quality in collaboration with FOGSI.
This was the function to commemorate 100 th birth centenary of Dr Sushila
The incidence of lung cancer is the third highest in the United States, and it is the leading cause of cancer-related mortality globally. Rates of lung cancer and deaths from the disease have been falling in the United States over the last two decades, while five-year survival rates have been rising.
Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...iosrjce
IOSR Journal of Dental and Medical Sciences is one of the speciality Journal in Dental Science and Medical Science published by International Organization of Scientific Research (IOSR). The Journal publishes papers of the highest scientific merit and widest possible scope work in all areas related to medical and dental science. The Journal welcome review articles, leading medical and clinical research articles, technical notes, case reports and others.
Establishment of a Rehabilitation Clinic for Colorectal Cancer. Will it End P...daranisaha
Colorectal cancer (CRC) is the third most common diagnosis and the second most lethal malignancy in both men and women.
To establish a rehabilitation clinic in the oncology department in hospitals and address its positive effect on colorectal cancer patients’ need.
How general internists can participate in the continuum of care for patients with cancer. (Talk given at Internal Medicine Grand Rounds, St. Elizabeth Hospital, General Santos City, 10 Feb 2021.)
2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinarFight Colorectal Cancer
Don’t miss our recap webinar from the American Society of Clinical Oncology Annual Conference (ASCO) where we discuss the latest research and treatments for colorectal cancer patients presented during the conference.
Dr. Dustin Deming, a medical oncologist and Fight CRC Medical Advisory Board Member will guide us through his findings. Dr. Deming brings a unique perspective as a researcher, oncologist and colorectal cancer survivor. In this webinar we will dive into the research and explain what it means for those living with colorectal cancer.
To share the knowledge from 2015 GI ASCO, Dr. Al Benson, one of FightCRC Medical Advisory Board members, and Andi Dwyer discuss key highlights as they pertain to colorectal cancer from the symposium and what they mean for patients.
Colorectal cancer (CRC) has potential to spread within the peritoneal cavity, and this transcoelomic
dissemination is termed “peritoneal metastases” (PM).The aim of this article was to summarise the current
evidence regarding CRC patients at high risk of PM. Colorectal cancer is the second most common cause of cancer
death in the UK. Prompt investigation of suspicious symptoms is important, but there is increasing evidence that
screening for the disease can produce significant reductions in mortality.High quality surgery is of paramount
importance in achieving good outcomes, particularly in rectal cancer, but adjuvant radiotherapy and chemotherapy
have important parts to play. The treatment of advanced disease is still essentially palliative, although surgery for
limited hepatic metastases may be curative in a small proportion of patients.
Awareness about Liver Cancer in Biotechnology Students_Crimson PublishersCrimsonpublishersCancer
Liver cancer is a major disease caused by sudden mutation occurred in the genes. To cure this disease gemcitabine seems to be affective. Gemcitabine is anticancer agent that has profile containing mild toxicity. It seems to be affective in solid tumors. To check its effectiveness, a questionnaire was developed and the awareness about liver cancer is checked in the post graduate students. All the students were fully aware of this disease.
Dr. Dustin Deming led us through a discussion on the latest research and treatments for colorectal cancer patients presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
A few of the topics covered include research on immunotherapy and trials studying:
– MSI-H (review of the Anti-PD-1 trial)
– HER2 amplification
– BRAF mutations
For more updates on colorectal cancer research, visit our blog: http://fightcolorectalcancer.org/category/research-treatment/
Looking to kick start your physical activity? Hoping to learn about how body movement can be a huge benefit for CRC patients and survivors? Curious about Climb for a Cure? Join this interactive webinar featuring Karia Coleman, MSK, personal trainer and athletic strength coach, and Fight CRC advocates as they discuss the importance, challenges, and joys of physical activity.
From bowel frequency, pain, and more, many colorectal cancer treatments lead to digestive side effects. Join this webinar with Dr. Cathy Eng to learn all about the digestive system, the side effects that are common due to CRC treatment, and how to manage those side effects.
Maine recently passed major colorectal cancer (CRC) policy at the state level. Join us to listen to their story and learn what worked well for CRC state advocacy!
Indiana just passed major colorectal cancer (CRC) policy this year. Join us to listen to their story and learn what worked well for CRC advocacy in Indiana!
Kentucky was one of the first states in the US to pass major colorectal cancer (CRC) policy. Join us to listen to their story and learn what worked well for CRC state advocacy!
Join Fight CRC in a webinar about biomarkers. In this session, Dr. Chris Lieu will focus the discussion on the NTRK biomarker, in addition to ctDNA, and Next-Generation Sequencing.
Join us as Eden Stotsky-Himelfarb, BSN, RN from Johns Hopkins Medicine discusses how to manage after a colorectal cancer diagnosis. In this session, she will cover understanding diagnoses, shared decision making, managing mental health, talking to family and colleagues, and more.
Some colorectal cancer treatments lead to side effects of the skin. In this webinar, Dr. Nicole LeBoeuf will discuss these specific side effects. She will talk about why they occur, how to prepare for them, and how to manage them.
Hear about the latest breaking colorectal cancer research! Fight CRC will be joined by Dr. Axel Grothey who will spend the hour detailing the research presented at the 2020 Gastrointestinal (GI) Cancers Symposium hosted by the American Society of Clinical Oncology.
Anticipating the end of life and making decisions about medical care at this time can be difficult and distressing for people with cancer and their loved ones. However, it is incredibly important to plan for the transition to end-of-life care.
In this webinar, we will discuss questions to ask when considering an end to curative treatment, what to expect with hospice and end-of-life care, a new medical care team, advance directives and healthcare proxies, options for pain, the role of caregivers and loved ones, and more.
In this webinar, Dr. Angela Nicholas, Dr. Chris Heery, and Wenora Johnson discuss all things clinical trials. Dr. Nicholas, a family practitioner and caregiver to her late husband, John MacCleod will dive into her experience searching for clinical trials along with advice to those currently searching, or planning on searching in the future. Dr. Heery, Chief Medical Officer for Precision Biosciences will spend time dispelling myths around clinical trials and challenges to enrollment, and Wenora Johnson, a stage III colon cancer survivor will describe the process and her point of view curating trials in the Fight CRC trial finder.
In this webinar, Dr. Popp will discuss everything you need to know about palliative care! This is an important webinar for colorectal cancer patients and their loved ones.
eeling worn out and exhausted all the time? You may be experiencing cancer-related fatigue. Tune in to this webinar to learn what cancer-related fatigue is, how to spot it, and how to manage it.
In this webinar, Dr. Azad discusses colorectal cancer recurrence. She addresses things to do to help reduce the risk of recurrence, in addition to what steps should be taken if colon or rectal cancer returns.
Join Fight CRC and Dr. Scott Kopetz to learn about the latest breaking colorectal cancer research from the American Society of Clinical Oncology 2019 Annual Conference.
May 2019 – What You Need to Know About Chemotherapy Induced Neuropathy WebinarFight Colorectal Cancer
Neuropathy is a common side effect for colorectal cancer patients. It is a side effect that can be incredibly challenging to manage, and can affect daily living. Join this informative webinar to learn all about neuropathy—why it happens, how to prepare for it, and methods to try and reduce its effects. This is an important webinar for all survivors and patients! Dana will speak from both the medical professional and patient angle, as she is a colon cancer survivor herself!
A cancer diagnosis and cancer treatment can be traumatic. An experience with cancer can lead to serious psychological distress that should be addressed. In this webinar, Schuyler Cunningham, Clinical Social Worker, talks about what trauma is, how to identify it, and what steps to take next.
There are countless questions when it comes to medical cannabis and colorectal cancer: How can it help? How do you get it? Are there drug interactions with chemo? What are the side effects? Is it legal where I live?
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
RESEARCH & TREATMENT NEWS: Highlights from the 2014 GI Cancer Symposium
1. ASCO GI 2014 Update:
Personalized Medicine in CRC
Colon Cancer Alliance/Fight Colorectal Cancer
Webinar
February 19, 2014
Allyson J. Ocean, M.D.
Associate Professor of Clinical Medicine
Weill Cornell Medical College
2. ASCO GI 2014 Update
Allyson Ocean, M.D.
Melissa Bjorklund
Randy Henniger
Kim Ryan
3. ABOUT THE COLON CANCER ALLIANCE
Our mission is to knock colon cancer out of the top three
cancer killers. We are doing this by championing prevention,
funding cutting-edge research and providing the highest
quality patient support services.
In 2013, the Colon Cancer Alliance:
5. PATIENT SUPPORT PROGRAMS
Whether you’re a patient, survivor, family
member or advocate, we’re here for you.
•Patient Support Navigator Program
•Toll-free Helpline
•My CCA Support Online Community
•Buddy Program
•Blue Note Fund Financial Assistance
•Community Outreach Volunteer
Program
6. GET INVOLVED
March is National Colon Cancer Awareness Month!
Find an event or join us at coloncancermonth.org.
Upcoming events:
March 1 – Colon Cancer Awareness Month Kickoff
March 5 – Colon Cancer Survivor Day
March 7 – National Dress in Blue Day
8. Fight Colorectal Cancer
FightColorectalCancer.org or call 1-877-427-2111
Mission
Fight Colorectal Cancer demands a cure for colon and rectal cancer. We
educate and support patients, push for changes in policy that will increase and
improve research, and empower survivors to raise their voices against the status
quo.
Facebook.com/FightCRC
Twitter.com/FightCRC
YouTube.com/FightCRC
Instagram.com/FightCRC
Pinterest.com/FightCRC
9. CRC: Epidemiology in 2013
Fourth most common cancer
diagnosis in US[1]
Estimated 142,820 new cases in
2013; 1:1 male:female ratio[2]
Second leading cause of cancer
deaths in 2013 (estimated 50,830
deaths)[1]
Steady decrease in age-adjusted
incidence rates of distal colon,
proximal colon, and rectal cancers
in 1976-2005[4]
Death Rates in 2008,
per 100,000[3], %
Male
Female
All races
20.2
14.1
White
19.5
13.6
Black
29.8
19.8
Asian/Pacific Islander
13.1
9.6
American Indian/ Alaska
Native
18.8
14.6
Hispanic
15.3
10.2
1. American Cancer Society. Cancer facts & figures. 2013. 2. Siegel R, et al. CA Cancer
J Clin. 2012;62:10-29. 3. SEER. Stat fact sheets: colon and rectum. 4. Cheng L, et al. Am Clin Oncol.
2011;34:573-580.
10. Colorectal Cancer in Young Adults
Incidence rising SHARPLY in younger adults in U.S.
Researchers analyzed SEER data for 383,241 patients
in whom CRC diagnosed between 1975 and 2010
Age-adjusted incidence of CRC fell steadily among >50
Annual percentage change in rates rose in patients
aged 35-49 at diagnosis and ESPECIALLY aged 20-34
Results similar for colon and rectum
Study lead author, Dr. Christina Bailey, M.D. Anderson, ASCO GI 2014 Poster
11. What does this mean for young
adults?
Predictive model suggested that if observed trends
persist between 2010 and 2030, incidences of colon
cancer and rectal cancer will rise by 90% and 124%
respectively among 20-34 yo and by 28% and 46%
respectively in 35-49 yo
Why? Possible reasons: Increasing obesity rates,
physical inactivity, diet high in fat and red meat
Primary care docs may be more alert for this cancer in
young adults with symptoms like rectal bleeding
12. Colorectal Cancer: Stage at Diagnosis
Stage
0
Stage IV
7%
19%
Stage I
24%
Stage III
25%
Stage II
25%
National Cancer Database.
13. Colorectal Cancer:
Standard Therapy Algorithm
Stage
Colon
Rectal
I (T1-T2, N0, M0)
Surgery only
Surgery only
II (T3-T4, N0, M0)
Surgery ±
chemotherapy
III (Tany, N+, M0)
Surgery
chemotherapy
Chemoradiation surgery
chemotherapy
OR
Surgery chemoradiation
+ chemotherapy
IV (Tany, Nany, M1)
Chemotherapy ±
surgery
NCCN. Clinical practice guidelines in oncology: colon cancer. v.1.2014.
Chemotherapy ±
surgery
15. Oncotype DX News
Through an analysis of physician recommendations and patient
treatment preferences before and after receiving the Oncotype
DX colon cancer test results, this study demonstrated that the
test greatly increased concordance between physician and
patient treatment choice (from 66 percent to 96 percent).
Recurrence Score® result influenced a majority of patients'
treatment decisions (85 percent) and physicians' treatment
recommendations (69 percent), and it increased physicians'
confidence in their own recommendations (84 percent).
Patients' anxiety was also significantly reduced, which may
improve adherence to their treatment plan and ultimately lead
to better health outcomes.
16. Oncotype DX
The review of four validation studies of the Oncotype DX
colon cancer test (3,315 patients) with early stage colon
cancer, consistently demonstrated a significant association
(p < 0.05) between the test results and recurrence risk and
cancer-specific survival.
Three decision impact studies with a total of 502 patients
showed that the test changed treatment
recommendations in 29 to 45 percent of stage II colon
cancer cases, leading to a net reduction in adjuvant
chemotherapy use.
17. Final Results of NSABP R-04
Phase III randomized trial in neoadjuvant rectal cancer- mature
results presented
Combining preoperative radiation with oral capecitabine
(Xeloda) was equally as effective as our old standby, infusional
5-FU chemo, in terms of local-regional recurrence rates
Largest clinical trial showing no difference in clinical benefit
Provides for better quality of life for patients
Not tied down to getting a catheter treatment and able to take
an oral agent
Adding oxaliplatin to either treatment did not improve clinical
response rates
Allegra et. al ASCO GI 2014 Abstract 390
18. Phase III GCR-3 Trial
Spanish trial for pre-operative (neoadjuvant) treatment of rectal cancer
Tips the balance in favor of induction chemotherapy followed by
chemoradiotherapy and then surgery vs. the standard approach of
chemoradiotherapy followed by surgery and then adjuvant chemotherapy in
patients with locally advanced rectal cancer
Pathologic CR rates, locoregional recurrence, distant recurrence, diseasefree survival, and overall survival all proved similar between the two
approaches out to 5 years
Less acute toxicity and better compliance to chemotherapy component of
the regimens was identified with the induction approach vs. the standard
approach
Need large phase III randomized trials to definitively find best approach
ASCO GI 2014 Abstract 383
20. Personalizing Treatment in mCRC:
Considerations
Extent of disease
Intent of treatment
(palliative vs potentially
curative)
Performance score
Age
Comorbid illnesses
Previous adjuvant therapy
within 1 yr
Molecular markers
Organ function: hepatic and
renal
Risks for toxicity: active
CAD/CVD, proteinuria, active
bleeding, nonhealed wound,
allergy to mAb, neuropathy,
IBD, ILD, Gilberts
Convenience
Cost/resources
Patient preferences and
goals
21. Maintenance Capecitabine/Bevacizumab
Delays Disease Progression
Phase III CAIRO3 trial
Data provides guidance about how big a treatment holiday
to give patients following induction therapy
Maintenance treatment with Xeloda and Avastin after 6
cycles of CAPOX-B (Xeloda, Oxaliplatin, Avastin)
significantly prolonged time to disease progression
Overall survival benefit for maintenance treatment in
certain patient groups (synchronous disease with resection
of primary tumor and in patients with complete or partial
response as best response on induction treatment)
Koopman et. al ASCO GI 2014 LBA
22. Improving outcome for CRC patients
Studies focused on leveraging prognostic and predictive
information
More extensive genetic testing for RAS gene mutations
beyond routine analysis of K-RAS exon 2 may soon become
a new standard of care to pinpoint which patients stand to
benefit from anti-EGFR therapy
K-RAS mutations present in approximately 40-50% of mCRC
tumors
If K-RAS mutation present- can’t use Erbitux or Vectibix
Peeters et. al, ASCO GI 2014 Abstract LBA387
23. Irinotecan drug-eluting beads
(DEBIRI)
Addition of DEBIRI to 1st line FOLFOX in unresectable liver-limited
metastatic CRC enables downstaging and subsequent resection
in more than 1/3 of patients
Placement of the beads in the hepatic artery did not increase
chemotherapy toxicity or compromise overall treatment delivery
This phase II trial was conducted in 70 patients with CRC with
liver metastases
Irinotecan beads administered to hepatic artery during off week
of chemotherapy; outpatient procedure
Key is finding the patients most appropriate for this therapy
Martin et. al, ASCO GI 2014 Abstract 174
24. Thoughts/Conclusions/Questions
Personalized medicine: What does it mean for YOU?
Ask about the genetics of your tumor
Ask about the K-RAS mutations of your tumor
Ask about genome sequencing of your tumor
Take advantage of educational websites
CCA, Fight CRC, Michael’s Mission
Connect with other patients and survivors
Links to novel treatments